dihydroxyphenylalanine has been researched along with Neoplasm Metastasis in 51 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation." | 7.80 | 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014) |
| "In case of uncharacteristic patient complaints or slightly pathologic BSR or liver enzyme levels in patients, suffering from melanoma, the determination of 5-S-cysteinyldopa in the 24-h-urine may be of great diagnostic value." | 7.66 | [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients]. ( Graef, V; Hellwich, M; Paul, E; Ruppel, R, 1983) |
| "This study examines 5-S-cysteinyldopa, which is a melanoma-associated marker, and sialic acid whose increase appears to be a common feature of numerous cancers." | 7.66 | Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas. ( Berthelot, P; Decaux, F; Jardillier, JC; Kalis, B; Marnot, D; Warren, L, 1983) |
| "In a total of 1,828 determinations, urinary excretion of 5-S-Cysteinyldopa was studied over a period of three years in 384 patients treated for melanoma or with metastases of malignant melanoma." | 7.66 | [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations]. ( Graef, V; Paul, E; Ruppel, R, 1980) |
| "Determinations of the urinary excretion of 5-S-cysteinyldopa were performed in 571 patients previously treated by surgery for melanoma or melanoma metastasis." | 7.66 | 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis. ( Agrup, G; Agrup, P; Andersson, T; Hafström, L; Hansson, C; Jacobsson, S; Jönsson, PE; Rorsman, H; Rosengren, AM; Rosengren, E, 1979) |
| "Determination of urine cysteinyldopa excretion is the most sensitive chemical test for the detection of melanoma metastases and has been successfully applied during the Scandinavian winter, when sun irradiation is low." | 7.66 | The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience. ( Nixon, PF, 1978) |
| "With the aid of gas chromatography and mass spectrometry a metabolite of dopa, 3-methoxytyrosine, has been demonstrated in the urine of 2 patients with melanoma metastases, the amounts excreted being 4." | 7.65 | Demonstration of 3-methoxytyrosine in the urine of melanoma patients. ( Agrup, G; Bengtsson, M; Falck, B; Persson, K; Rorsman, H; Rosengren, AM; Rosengren, E, 1976) |
| "A newly discovered amino acid, 5-S-cysteinyldopa, present in the urine of healthy subjects is excreted in pathological amounts in many patients suffering from melanoma metastases." | 7.65 | 5-S-cysteinyldopa in the urine of melanoma patients. ( Agrup, G; Agrup, P; Andersson, T; Falck, B; Hansson, JA; Jacobsson, S; Rorsman, H; Rosengren, AM; Rosengren, E, 1977) |
| "This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation." | 3.80 | 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014) |
| "In case of uncharacteristic patient complaints or slightly pathologic BSR or liver enzyme levels in patients, suffering from melanoma, the determination of 5-S-cysteinyldopa in the 24-h-urine may be of great diagnostic value." | 3.66 | [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients]. ( Graef, V; Hellwich, M; Paul, E; Ruppel, R, 1983) |
| "This study examines 5-S-cysteinyldopa, which is a melanoma-associated marker, and sialic acid whose increase appears to be a common feature of numerous cancers." | 3.66 | Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas. ( Berthelot, P; Decaux, F; Jardillier, JC; Kalis, B; Marnot, D; Warren, L, 1983) |
| "In a total of 1,828 determinations, urinary excretion of 5-S-Cysteinyldopa was studied over a period of three years in 384 patients treated for melanoma or with metastases of malignant melanoma." | 3.66 | [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations]. ( Graef, V; Paul, E; Ruppel, R, 1980) |
| "Determinations of the urinary excretion of 5-S-cysteinyldopa were performed in 571 patients previously treated by surgery for melanoma or melanoma metastasis." | 3.66 | 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis. ( Agrup, G; Agrup, P; Andersson, T; Hafström, L; Hansson, C; Jacobsson, S; Jönsson, PE; Rorsman, H; Rosengren, AM; Rosengren, E, 1979) |
| "Determination of urine cysteinyldopa excretion is the most sensitive chemical test for the detection of melanoma metastases and has been successfully applied during the Scandinavian winter, when sun irradiation is low." | 3.66 | The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience. ( Nixon, PF, 1978) |
| "With the aid of gas chromatography and mass spectrometry a metabolite of dopa, 3-methoxytyrosine, has been demonstrated in the urine of 2 patients with melanoma metastases, the amounts excreted being 4." | 3.65 | Demonstration of 3-methoxytyrosine in the urine of melanoma patients. ( Agrup, G; Bengtsson, M; Falck, B; Persson, K; Rorsman, H; Rosengren, AM; Rosengren, E, 1976) |
| "A newly discovered amino acid, 5-S-cysteinyldopa, present in the urine of healthy subjects is excreted in pathological amounts in many patients suffering from melanoma metastases." | 3.65 | 5-S-cysteinyldopa in the urine of melanoma patients. ( Agrup, G; Agrup, P; Andersson, T; Falck, B; Hansson, JA; Jacobsson, S; Rorsman, H; Rosengren, AM; Rosengren, E, 1977) |
| "Information on evaluation of brain metastases is limited but encouraging." | 2.48 | Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. ( Calabria, F; Chiaravalloti, A; Di Pietro, B; Grasso, C; Schillaci, O, 2012) |
| "The power of (18)F-FDOPA PET to predict disease progression was evaluated with the Kaplan-Meier and Cox regression methods." | 1.40 | (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. ( Allen-Auerbach, M; Chen, W; Czernin, J; DeSalles, AA; Lizarraga, KJ; Phelps, ME; Yong, WH, 2014) |
| "(68)Ga-DOTA-TATE PET delineated metastases in 54 of 55 positive metastatic tumour regions in contrast to 29 of 55 delineated by (18)F-DOPA PET." | 1.35 | Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. ( Auernhammer, CJ; Bartenstein, P; Göke, B; Haug, A; Pöpperl, G; Schmidt, G; Tiling, R; Wängler, B, 2009) |
| "The greatest impact was observed for carcinoid tumors (50%: 11 of 22) and was clinically relevant in every case, followed by occult endocrine tumors (16%: four of 25), and was clinically relevant in three of the four cases, and noncarcinoid tumors (13%: 3 of 22), clinically relevant in only one case." | 1.35 | Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. ( Bouchard, P; Duron, F; Grangé, JD; Houry, S; Huchet, V; Kerrou, K; Lotz, JP; Montravers, F; Nataf, V; Rougier, P; Ruszniewski, P; Talbot, JN, 2009) |
| "The production of metastases and the differentiation of tumors in the present experiments appeared to be related to the genetic background of the mice and the epigenetic metabolic environment of tumors and cells." | 1.28 | Differentiation of new metastatic variants of B16 melanoma under different culture conditions. ( Ali-Mehidi, S; Aubert, C; Rouge, F; Voulot, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (72.55) | 18.7374 |
| 1990's | 2 (3.92) | 18.2507 |
| 2000's | 3 (5.88) | 29.6817 |
| 2010's | 9 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gornes, H | 1 |
| Vaysse, C | 1 |
| Deslandres, M | 1 |
| Perallon, R | 1 |
| Chantalat, E | 1 |
| Rimailho, J | 1 |
| de Hosson, LD | 1 |
| van der Loo-van der Schaaf, AM | 1 |
| Boellaard, R | 1 |
| van Snick, JH | 1 |
| de Vries, EGE | 1 |
| Brouwers, AH | 1 |
| Walenkamp, AME | 1 |
| Balogova, S | 1 |
| Talbot, JN | 2 |
| Nataf, V | 2 |
| Michaud, L | 1 |
| Huchet, V | 2 |
| Kerrou, K | 2 |
| Montravers, F | 2 |
| Lizarraga, KJ | 1 |
| Allen-Auerbach, M | 1 |
| Czernin, J | 1 |
| DeSalles, AA | 1 |
| Yong, WH | 1 |
| Phelps, ME | 1 |
| Chen, W | 1 |
| Imperiale, A | 1 |
| Rust, E | 1 |
| Gabriel, S | 1 |
| Detour, J | 1 |
| Goichot, B | 1 |
| Duclos, B | 1 |
| Kurtz, JE | 1 |
| Bachellier, P | 1 |
| Namer, IJ | 1 |
| Taïeb, D | 1 |
| Guo, S | 1 |
| Lin, CM | 1 |
| Xu, Z | 1 |
| Miao, L | 1 |
| Wang, Y | 1 |
| Huang, L | 1 |
| Papin-Michault, C | 1 |
| Bonnetaud, C | 1 |
| Dufour, M | 1 |
| Almairac, F | 1 |
| Coutts, M | 1 |
| Patouraux, S | 1 |
| Virolle, T | 1 |
| Darcourt, J | 1 |
| Burel-Vandenbos, F | 1 |
| Haug, A | 1 |
| Auernhammer, CJ | 1 |
| Wängler, B | 1 |
| Tiling, R | 1 |
| Schmidt, G | 1 |
| Göke, B | 1 |
| Bartenstein, P | 1 |
| Pöpperl, G | 1 |
| Lotz, JP | 1 |
| Ruszniewski, P | 1 |
| Rougier, P | 1 |
| Duron, F | 1 |
| Bouchard, P | 1 |
| Grangé, JD | 1 |
| Houry, S | 1 |
| Kauhanen, S | 1 |
| Schalin-Jäntti, C | 1 |
| Seppänen, M | 1 |
| Kajander, S | 1 |
| Virtanen, S | 1 |
| Schildt, J | 1 |
| Lisinen, I | 1 |
| Ahonen, A | 1 |
| Heiskanen, I | 1 |
| Väisänen, M | 1 |
| Arola, J | 1 |
| Korsoff, P | 1 |
| Ebeling, T | 1 |
| Sane, T | 1 |
| Minn, H | 1 |
| Välimäki, MJ | 1 |
| Nuutila, P | 1 |
| Calabria, F | 1 |
| Chiaravalloti, A | 1 |
| Di Pietro, B | 1 |
| Grasso, C | 1 |
| Schillaci, O | 1 |
| GJESSING, LR | 1 |
| BORUD, O | 1 |
| Ambrosini, V | 1 |
| Tomassetti, P | 1 |
| Rubello, D | 1 |
| Campana, D | 1 |
| Nanni, C | 1 |
| Castellucci, P | 1 |
| Farsad, M | 1 |
| Montini, G | 1 |
| Al-Nahhas, A | 1 |
| Franchi, R | 1 |
| Fanti, S | 1 |
| Paul, E | 2 |
| Graef, V | 2 |
| Ruppel, R | 2 |
| Hellwich, M | 1 |
| Marnot, D | 1 |
| Decaux, F | 1 |
| Berthelot, P | 1 |
| Kalis, B | 1 |
| Jardillier, JC | 1 |
| Warren, L | 1 |
| Bánfalvi, T | 1 |
| Bezzegh, A | 1 |
| Edesné, BM | 1 |
| Fejös, Z | 1 |
| Liszkay, G | 1 |
| Schumann, B | 1 |
| Kremmer, T | 1 |
| Ottó, S | 1 |
| Gilde, K | 1 |
| Agrup, G | 8 |
| Falck, B | 6 |
| Kennedy, BM | 1 |
| Rorsman, H | 13 |
| Rosengren, AM | 9 |
| Rosengren, E | 12 |
| Andersson, T | 4 |
| Persson, K | 2 |
| Agrup, P | 3 |
| Jacobsson, S | 4 |
| Bengtsson, M | 1 |
| Hansson, JA | 1 |
| Hafström, L | 1 |
| Hansson, C | 1 |
| Jönsson, PE | 1 |
| Nixon, PF | 1 |
| Dy, V | 1 |
| Watson, RC | 1 |
| Exelby, PR | 1 |
| Hajdu, SI | 1 |
| Helson, L | 1 |
| Aubert, C | 3 |
| Rouge, F | 2 |
| Foa, C | 1 |
| Lipcey, C | 1 |
| Cesarini, JP | 2 |
| Daveau, M | 1 |
| Picard, F | 1 |
| Fournier, E | 1 |
| Rivat, L | 1 |
| Rivat, C | 1 |
| Prota, G | 1 |
| Lagrange, C | 1 |
| Blois, MS | 2 |
| Banda, PW | 1 |
| Meunier, M | 1 |
| Ali-Mehidi, S | 1 |
| Voulot, C | 1 |
| Hu, F | 1 |
| Woodward, WR | 1 |
| Peterson, LL | 1 |
| Haberman, HF | 1 |
| Menon, IA | 1 |
| Minton, JP | 6 |
| Dickey, RP | 4 |
| Vogel, CL | 1 |
| Dhru, D | 1 |
| Ghozian, D | 1 |
| Amor, B | 1 |
| Delbarre, F | 1 |
| Sohn, N | 1 |
| Gang, H | 1 |
| Gumport, SL | 1 |
| Goldstein, M | 1 |
| Deppisch, LM | 1 |
| Greer, M | 1 |
| Anton, AH | 1 |
| Williams, CM | 1 |
| Eichhorn, F | 1 |
| Rutenberg, A | 1 |
| Kott, E | 1 |
| Duke, PS | 1 |
| Domopoulos, HB | 1 |
2 reviews available for dihydroxyphenylalanine and Neoplasm Metastasis
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorode | 2013 |
Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT.
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; | 2012 |
3 trials available for dihydroxyphenylalanine and Neoplasm Metastasis
| Article | Year |
|---|---|
Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Topics: Adult; Aged; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Cell Proliferation; Di | 2011 |
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Digestive System Neoplasms; Dihydroxyphenylalanine; | 2007 |
[Letter: L. Dopa and bone metastases in breast cancer].
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combination | 1974 |
46 other studies available for dihydroxyphenylalanine and Neoplasm Metastasis
| Article | Year |
|---|---|
Discovery of a neuroendocrine tumor of the caecum by mammary metastasis using 18F-DOPA-PET.
Topics: Adult; Breast Neoplasms; Cecal Neoplasms; Dihydroxyphenylalanine; Female; Humans; Neoplasm Metastasi | 2018 |
Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.
Topics: Aged; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Me | 2019 |
(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Topics: Adult; Aged; Brain Neoplasms; Diagnosis, Differential; Dihydroxyphenylalanine; Disease Progression; | 2014 |
18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Topics: Adult; Aged; Cohort Studies; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Multimodal I | 2014 |
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromatography, High Pressure Liquid; C | 2014 |
Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers.
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Female; Gene Expression Regulation, Neoplastic; Humans; Lar | 2016 |
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neopl | 2009 |
Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors.
Topics: Adult; Biopsy; Carcinoid Tumor; Dihydroxyphenylalanine; Endocrine Gland Neoplasms; Fluorodeoxyglucos | 2009 |
STUDIES OF FUNCTIONAL NEURAL TUMORS. VII. URINARY EXCRETION OF PHENOLIC PYRUVIC ACIDS.
Topics: Alkylation; Child; Chromatography; Dihydroxyphenylalanine; Humans; Metabolism; Neoplasm Metastasis; | 1965 |
[5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Topics: Cysteinyldopa; Dihydroxyphenylalanine; Humans; Isomerism; Melanoma; Neoplasm Metastasis; Skin Neopla | 1983 |
Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Topics: Adult; Aged; Cysteinyldopa; Dihydroxyphenylalanine; Female; Humans; Male; Melanoma; Middle Aged; Neo | 1983 |
[5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Topics: BCG Vaccine; Cysteinyldopa; Dihydroxyphenylalanine; Female; Humans; Male; Melanoma; Melphalan; Neopl | 1980 |
[Determination of serum S-100 protein and 5-S-cysteinyl-DOPA levels in melanoma patients].
Topics: Dihydroxyphenylalanine; Female; Humans; Male; Melanoma; Neoplasm Metastasis; S100 Proteins | 1999 |
Formation of cysteinyldopa from glutathionedopa in melanoma.
Topics: Animals; Cysteine; Depression, Chemical; Dihydroxyphenylalanine; Glutathione; Guinea Pigs; Humans; K | 1975 |
5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
Topics: Adult; Breast Neoplasms; Cysteine; Dihydroxyphenylalanine; Humans; Liver Neoplasms; Lung Neoplasms; | 1975 |
Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm | 1975 |
Demonstration of 3-methoxytyrosine in the urine of melanoma patients.
Topics: Chromatography, Gas; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Mass Spectrometry; Mela | 1976 |
5-S-cysteinyldopa in the urine of melanoma patients.
Topics: Adult; Aged; Cysteinyldopa; Dihydroxyphenylalanine; Eye Neoplasms; Female; Humans; Male; Melanoma; M | 1977 |
5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Topics: Adult; Aged; Cysteinyldopa; Dihydroxyphenylalanine; Female; Hair Color; Humans; Lymphatic Metastasis | 1979 |
The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
Topics: Adolescent; Adult; Australia; Cysteinyldopa; Dihydroxyphenylalanine; Humans; Melanoma; Neoplasm Meta | 1978 |
Improved management of stage III neuroblastoma.
Topics: Age Factors; Antineoplastic Agents; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Human | 1979 |
5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
Topics: Adult; Aged; Cysteinyldopa; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Melanoma; Micros | 1977 |
[Urinary evaluation of 5-S-cysteinyldopa and seric evaluation of IgG4 subclass during follow-up of 27 primitive malignant melanomas (author's transl)].
Topics: Cysteinyldopa; Dihydroxyphenylalanine; Humans; Immunoglobulin G; Melanoma; Neoplasm Metastasis | 1978 |
[Melanoma metabolites (proceedings)].
Topics: Cysteinyldopa; Dihydroxyphenylalanine; Humans; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 1978 |
Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
Topics: Cysteinyldopa; Dihydroxyphenylalanine; Humans; Melanoma; Neoplasm Metastasis | 1977 |
Catechols in primary and metastatic human malignant melanoma cells in monolayer culture.
Topics: Adult; Clone Cells; Dihydroxyphenylalanine; Female; Humans; Male; Melanocytes; Melanoma; Middle Aged | 1976 |
Detection of occult metastatic melanoma by urine chromatography.
Topics: Chromatography, Ion Exchange; Cysteinyldopa; Dihydroxyphenylalanine; Female; Humans; Male; Melanoma; | 1976 |
[Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
Topics: Creatinine; Cysteine; Dihydroxyphenylalanine; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 1975 |
[Chemical diagnosis of melanoma].
Topics: Cysteine; Dihydroxyphenylalanine; Humans; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 1976 |
Differentiation of new metastatic variants of B16 melanoma under different culture conditions.
Topics: Animals; Cell Transformation, Neoplastic; Dihydroxyphenylalanine; Genetic Variation; Lung Neoplasms; | 1992 |
Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
Topics: Animals; Cysteinyldopa; Dihydroxyphenylalanine; Male; Melanoma, Experimental; Mice; Mice, Inbred C57 | 1988 |
Presence and properties of tyrosinase in sera of melanoma-bearing animals.
Topics: Animals; Blood; Catechol Oxidase; Centrifugation, Density Gradient; Chromatography; Cricetinae; Dihy | 1971 |
Prolactin, F.S.H., and L.H. in breast cancer: effect of levodopa and oophorectomy.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenylalanine; Female; Follicle Stimulating Hormon | 1972 |
Dopa and 5-S-cysteinyldopa in malignant melanoma in Ugandan Africans.
Topics: Adult; Aged; Black People; Cysteine; Dihydroxyphenylalanine; Female; Humans; Male; Melanoma; Middle | 1974 |
5-S-cysteinyldopa in melanomas of Caucasians.
Topics: Adult; Aged; Chromatography; Cysteine; Dihydroxyphenylalanine; Female; Fluorometry; Hair; Humans; Me | 1974 |
Prolactin and human breast cancer.
Topics: Antipsychotic Agents; Bone Neoplasms; Breast Neoplasms; Castration; Dihydroxyphenylalanine; Estrogen | 1974 |
Melanocytic neoplasms.
Topics: Dihydroxyphenylalanine; Epinephrine; Humans; Melanins; Melanocytes; Melanoma; Mustard Compounds; Neo | 1974 |
L-Dopa effect on prolactin, follicle-stimulating hormone, and luteinizing hormone in women with advanced breast cancer: a preliminary report.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenyl | 1972 |
Levodopa test to predict response of carcinoma of the breast to surgical ablation of endocrine glands.
Topics: Adenocarcinoma; Adult; Analgesics; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenylalanine; Female; | 1973 |
Determination of 5-S-cysteinyldopa in melanomas with a fluorimetric method.
Topics: Animals; Black People; Cysteine; Dihydroxyphenylalanine; Dopamine; Fluorometry; Guinea Pigs; Hair; H | 1973 |
Proceedings: The response of breast cancer patients with bone pain to L-dopa.
Topics: Adrenalectomy; Bone Neoplasms; Breast Neoplasms; Castration; Dihydroxyphenylalanine; Female; Humans; | 1974 |
Generalized melanosis secondary to malignant melanoma. Report of a case with serum and tissue tyrosinase studies.
Topics: Catechol Oxidase; Dihydroxyphenylalanine; Female; Humans; Lung Neoplasms; Melanins; Melanoma; Melano | 1969 |
Levodopa relief of bone pain from breast cancer.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenylalanine; Female; Humans; Neoplasm Metastasis | 1972 |
Failure of enzyme inhibition therapy for malignant melanoma.
Topics: Adult; Brain Neoplasms; Dihydroxyphenylalanine; Dopamine; Enzyme Repression; Epinephrine; Humans; Ma | 1969 |
Fluorometric method for quantitatively estimating urinary dihydroxyphenylethylamine (dopamine), dihydroxyphenylalanine (dopa), and dihydroxyphenylacetic acid (dopac).
Topics: Aluminum; Bone Neoplasms; Dihydroxyphenylalanine; Dopamine; Electrophoresis; Ethylenediamines; Fluor | 1971 |
One-dimensional paper chromatographic method for determination of urinary homovanillic acid.
Topics: Adolescent; Adult; Aged; Chromatography, Paper; Dihydroxyphenylalanine; Female; Humans; Male; Melani | 1968 |